Compare Stocks → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:ALTNASDAQ:CPRXNASDAQ:ETNBOTCMKTS:WIZP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.39$1.60$0.59▼$2.48$291.02M0.794.40 million shs2.55 million shsALTAltimmune$6.89-2.1%$9.54$2.09▼$14.84$488.43M0.055.53 million shs3.21 million shsCPRXCatalyst Pharmaceuticals$15.34-4.1%$15.38$11.09▼$17.78$1.81B0.891.42 million shs1.49 million shsETNB89bio$8.88-3.1%$11.08$6.57▼$22.93$830.28M1.041.25 million shs675,417 shsWIZPMawson Infrastructure Group$1.11+11.0%$1.55$0.07▼$1.45$539.82M1.77141,517 shs270,275 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-9.15%-24.04%-0.71%+92.23%ALTAltimmune-2.13%-17.98%-21.17%-25.51%+15.41%CPRXCatalyst Pharmaceuticals-4.13%-2.97%-6.41%+5.36%-11.48%ETNB89bio-3.06%-12.43%-25.50%-19.57%-49.32%WIZPMawson Infrastructure Group-2.91%-9.91%-28.57%-55.56%-68.85%You’re invited: Biggest crypto event of 2024 (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.7801 of 5 stars3.52.00.04.03.20.80.6ALTAltimmune1.1439 of 5 stars3.32.00.00.01.91.70.0CPRXCatalyst Pharmaceuticals4.9877 of 5 stars4.51.00.03.92.93.34.4ETNB89bio1.1708 of 5 stars4.31.00.00.00.01.70.0WIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$5.00259.71% UpsideALTAltimmune2.67Moderate Buy$15.00117.71% UpsideCPRXCatalyst Pharmaceuticals3.00Buy$26.4372.29% UpsideETNB89bio2.67Moderate Buy$28.83224.70% UpsideWIZPMawson Infrastructure GroupN/AN/AN/AN/ACurrent Analyst RatingsLatest ALT, AKBA, WIZP, ETNB, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$29.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/27/2024CPRXCatalyst PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$29.003/27/2024ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.003/22/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/14/2024CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.003/14/2024CPRXCatalyst PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.003/13/2024ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M1.50N/AN/A($0.16) per share-8.69ALTAltimmune$430K1,135.89N/AN/A$2.75 per share2.51CPRXCatalyst Pharmaceuticals$398.20M4.55$2.03 per share7.56$3.30 per share4.65ETNB89bioN/AN/AN/AN/A$5.75 per shareN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/13/2024 (Estimated)ALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)CPRXCatalyst Pharmaceuticals$71.41M$0.6125.157.040.8617.93%26.56%22.13%5/8/2024 (Estimated)ETNB89bio-$142.19M-$2.01N/AN/AN/AN/A-31.01%-27.84%5/2/2024 (Estimated)WIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ALatest ALT, AKBA, WIZP, ETNB, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million2/29/2024Q4 2023ETNB89bio-$0.49-$0.50-$0.01-$0.50N/AN/A2/28/2024Q4 2023CPRXCatalyst Pharmaceuticals$0.45$0.49+$0.04$0.67$105.78 million$110.57 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03ALTAltimmuneN/A17.2617.26CPRXCatalyst PharmaceuticalsN/A2.882.68ETNB89bio0.0520.0420.04WIZPMawson Infrastructure GroupN/A1.131.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALTAltimmune78.05%CPRXCatalyst Pharmaceuticals79.22%ETNB89bioN/AWIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%ALTAltimmune4.10%CPRXCatalyst Pharmaceuticals12.10%ETNB89bio4.40%WIZPMawson Infrastructure GroupN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics167209.37 million201.33 millionOptionableALTAltimmune5970.89 million67.99 millionOptionableCPRXCatalyst Pharmaceuticals167118.01 million103.73 millionOptionableETNB89bio7093.50 million89.39 millionOptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableALT, AKBA, WIZP, ETNB, and CPRX HeadlinesSourceHeadlineMawson Infrastructure Group adds new customer at Midland bitcoin facilitybizjournals.com - December 20 at 11:39 AMMawson announces agreement for half of Midland bitcoin facility capacitybizjournals.com - October 19 at 5:32 PMMawson Infrastructure reports BTC production of 69 in July, down 3% M/Mseekingalpha.com - August 24 at 6:28 PMH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)markets.businessinsider.com - August 24 at 7:44 AMMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location Servicestechnews.tmcnet.com - July 25 at 10:20 AMMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023businesswire.com - July 19 at 10:01 AMMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023technews.tmcnet.com - June 14 at 10:10 AMMawson Infrastructure Group names new president, CEObizjournals.com - May 22 at 12:56 PMWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining Investorsmsn.com - April 11 at 10:13 AMEarnings Outlook For Mawson Infrastructuremsn.com - November 12 at 8:40 PMBitcoin Miner CleanSpark Buys Mawson Site as Consolidation Risesfinance.yahoo.com - September 11 at 12:26 AMMawson Infrastructure Group Inc. To Sell Sandersville, Georgia Bitcoin Mining Facility including 6468 ASIC Bitcoin Miners To CleanSpark, Inc. For Up To $42.5 Millionbenzinga.com - September 9 at 10:20 AMWhy Bitcoin- And Ethereum-Related Stock CleanSpark Is Rising Todaybenzinga.com - September 9 at 10:20 AMMawson Infrastructure Group Inc. Announces July 2022 Bitcoin Self-Mining, Hosting Co-location, Energy Demand Response and Operational Updatefinance.yahoo.com - August 25 at 10:24 AMMawson Infrastructure Group Inc. Schedules Second Quarter Results Webcast for 5:30 p.m. ET on August 22, 2022benzinga.com - August 18 at 9:55 AMBitcoin Miner Mawson Infrastructure Produced 185 Bitcoin In Record-Breaking Maybitcoinmagazine.com - June 16 at 3:23 PMMawson to Develop New Bitcoin Mining Site in Texasfinance.yahoo.com - May 17 at 2:50 AMMawson Infrastructure Group Inc. Announces New 120 Megawatt Bitcoin Mining Facility in Texas, USAtmcnet.com - May 16 at 9:34 AMTexas Pacific Land Corporation, Mawson Infrastructure Group Inc., and JAI Energy Announce New Bitcoin Mining Venture in West Texastmcnet.com - May 16 at 9:34 AMMawson Infrastructure Group discusses Q3 highlights including Quinbrook renewable energy partnershipproactiveinvestors.com - December 14 at 11:45 PMAudacious Secures $20M Funding & Closes $3.1M Non-Brokered Private Placement Tranchebenzinga.com - December 11 at 11:01 PMEssential Investment? This REIT Believes in Cannabis-Related Real Estatebenzinga.com - December 9 at 6:25 PMSouth Dakota's Supreme Strikes Down Recreational Cannabis Vote, Overturning People's Willbenzinga.com - November 28 at 6:55 PM10 Weed Strains For People Who Like Cheesebenzinga.com - November 8 at 12:11 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityTop 3 Stocks Bought By Members of Congress In the First QuarterMarch 25, 2024 8:55 AMView Top 3 Stocks Bought By Members of Congress In the First QuarterAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia Treatment3M Spun Off Its Health Division, Is It Still A Buy?April 4, 2024 7:47 AMView 3M Spun Off Its Health Division, Is It Still A Buy?4 Dividend Aristocrats Trading at a DiscountApril 1, 2024 6:10 AMView 4 Dividend Aristocrats Trading at a DiscountAll Headlines Company DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.AltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Catalyst PharmaceuticalsNASDAQ:CPRXCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.89bioNASDAQ:ETNB89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Mawson Infrastructure GroupOTCMKTS:WIZPMawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.